| Critètes d'éligibilité |
-
Patients with the first occurrence of any tumor of the kidney identified on CT scan or MRI are eligible for this study; histologic diagnosis is not required prior to enrollment but is required for all patients once on study
-
Eligible tumors include (but are not limited to):
-
Nephroblastic tumors
-
Nephroblastoma (Wilms' tumor) (favorable histology, anaplasia [diffuse, focal])
-
Nephrogenic rests and nephroblastomatosis
-
Cystic nephroma and cystic partially differentiated nephroblastoma
-
Metanephric tumors (metanephric adenoma, metanephric adenofibroma, metanephric stromal tumor)
-
Mesoblastic nephroma (cellular, classic, mixed)
-
Clear cell sarcoma
-
Rhabdoid tumor (any malignant rhabdoid tumor occurring outside the central nervous system [CNS])
-
Renal epithelioid tumors of childhood (papillary renal cell carcinoma, medullary renal cell carcinoma, renal tumors associated with Xp11.2 translocations, oncocytic renal neoplasms after neuroblastoma)
-
Angiolipoma
-
Ossifying renal tumor of infancy
-
Patients with the first occurrence of the following tumors are also eligible:
-
Extrarenal nephroblastoma or extrarenal neprogenic rests
-
Malignant rhabdoid tumor occurring anywhere outside the Central Nervous System
-
Required specimens, reports, and copies of imaging studies must be available for submission or must become available during the required timeframe
-
For ALL patients (with exception of bilateral, bilaterally predisposed or unilateral tumor in solitary kidney planning to enroll without biopsy), the following submissions are required:
-
A complete set of recut hematoxylin and eosin (H & E) slides**
-
Representative formalin-fixed paraffin-embedded tissue block or if a block is unavailable, 10 unstained slides from a representative block of tumor**
-
Institutional pathology report, transmittal form and pathology checklist
-
Copies of images and institutional reports of CT and/or MRI abdomen and pelvis
-
Copies of images and institutional report of CT chest for all malignant tumors
-
Institutional surgical report(s)
-
Tissue must be from diagnosis, prior to any chemotherapy or radiation
-
For patients with clinical features and required imaging findings consistent with the eligibility for the bilateral study, AREN0534 (or successor study), confirmed by central review, biopsy is not required; however, if biopsy is done, tissue must be submitted as for other renal tumors, and initial risk assignment will require pathology and surgical rapid central reviews; transmittal form and pathology checklist are also needed
-
Patients with extrarenal Wilms tumor must have tumor tissue available for central review
-
Patients with extra-CNS malignant rhabdoid tumor must have tumor tissue available for central review
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
|
CHUL ET CENTRE MERE-ENFANT SOLEIL
Actif en recrutement
Groupe d'étude en oncologie du Québec